Sinovac vaccine more than 50% effective, but data delayed
24 December 2020 - 08:00
Sao Paulo — A Covid-19 vaccine developed by Chinese pharmaceutical firm Sinovac Biotech was found to be more than 50% effective in a Brazilian clinical trial, though researchers delayed releasing more information at the request of the company.
A 50% efficacy rate is a minimum standard set by US regulators for emergency authorisation of Covid vaccines. Messenger RNA vaccines from Moderna and Pfizer Inc. have produced far better results, reducing symptomatic Covid cases by well over 90% in giant trials...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.